The Emerging World of JAK Inhibitors

Uprety, Shraddha

Publication:
The Emerging World of JAK Inhibitors

creativeworkseries.issn	ISSN 2091-0231 eISSN 2091-167X
dc.contributor.author	Uprety, Shraddha
dc.date.accessioned	2025-10-09T09:09:32Z
dc.date.available	2025-10-09T09:09:32Z
dc.date.issued	2024
dc.description	Author Biography Shraddha Uprety, Chitwan Medical College and Teaching Hospital Associate Professor, Chitwan Medical College and Teaching Hospital, Nepal
dc.description.abstract	Abstract: The Janus Kinase inhibitors are a new emerging class of small molecules. These target the Janus Kinase proteins located on the cell membrane. Janus Kinase proteins regulate the cellular transcription of several proteins and act as mediators in several cytokine pathways. Dysregulation in these cytokine pathways is responsible for disorders like alopecia areata, psoriasis, vitiligo, lichen planus, and more in dermatology. Contrary to the injectable biologics, these Janus kinase inhibitors can be taken per oral route and have greater patient acceptability. In this review, we seek to discuss the various indications of Janus Kinase inhibitors and their side effects. We also strive to discuss the monitoring for this class of drugs.
dc.identifier	https://doi.org/10.3126/njdvl.v22i2.68527
dc.identifier.uri	https://hdl.handle.net/20.500.14572/2540
dc.language.iso	en_US
dc.publisher	Society of Dermatologists, Venereologists and Leprologists of Nepal (SODVELON)
dc.subject	Alopecia areata
dc.subject	Atopic Dermatitis
dc.subject	JAK inhibitors
dc.subject	Lichen Planus
dc.subject	Pruritus
dc.subject	Psoriasis
dc.subject	Vitiligo
dc.title	The Emerging World of JAK Inhibitors
dc.type	Article
dspace.entity.type	Publication
local.article.type	Editorial
oaire.citation.endPage	4
oaire.citation.startPage	1
relation.isJournalIssueOfPublication	cad24931-fc67-4ba8-9434-1063bb22b3e2
relation.isJournalIssueOfPublication.latestForDiscovery	cad24931-fc67-4ba8-9434-1063bb22b3e2
relation.isJournalOfPublication	b2ab7aab-75b0-4bd1-9ed0-b8a91c68201a